Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.

Inventors: Sanjay R. Chemburkar, Ketan Patel
Original Assignee: Abbott Laboratories
Primary Examiner: Kamal A. Saeed
Secondary Examiner: Robert Shiao
Current U.S. Classification: 548/204

View patent at USPTO
Search USPTO Assignment Database
Download USPTO Public PAIR data

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US5484801May 12, 1995Jan 16, 1996Abbott LaboratoriesPharmaceutical composition for inhibiting HIV protease
US5541206Apr 25, 1995Jul 30, 1996Abbott LaboratoriesRetroviral protease inhibiting compounds
US5559158Aug 31, 1994Sep 24, 1996Abbott LaboratoriesPharmaceutical composition
US5567823Jun 6, 1995Oct 22, 1996Abbott LaboratoriesProcess for the preparation of an HIV protease inhibiting compound
US5635523Apr 6, 1995Jun 3, 1997Abbott LaboratoriesRetroviral protease inhibiting compounds
US5648497Mar 24, 1995Jul 15, 1997Abbott LaboraotriesRetroviral protease inhibiting compounds
US5674882Mar 29, 1995Oct 7, 1997Abbott LaboratoriesRetroviral protease inhibiting compounds
US5725878May 4, 1995Mar 10, 1998Abbott LaboratoriesPharmaceutical composition comprising HIV protease inhibiting compounds

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US7364752Nov 10, 2000Apr 29, 2008Abbott LaboratoriesSolid dispersion pharamaceutical formulations
US8025899Aug 25, 2004Sep 27, 2011Abbott LaboratoriesSolid pharmaceutical dosage form
US8193367Dec 22, 2009Jun 5, 2012Abbott LaboratoriesPolymorph of a pharmaceutical

Claims

1. Substantially pure amorphous ritonavir.

2. The substantially pure amorphous ritonavir of claim 1 characterized by a glass transition from about 45° C. to about 49° C.

3. A composition comprising amorphous ritonavir.

4. The composition of claim 3, wherein said amorphous ritonavir is substantially pure.

5. The composition of claim 3, wherein greater than about 90% of ritonavir in said composition is amorphous ritonavir.

6. The composition of claim 3, wherein greater than about 95% of ritonavir in said composition is amorphous ritonavir.

7. The composition of claim 3, wherein greater than about 97% of ritonavir in said composition is amorphous ritonavir.

Drawings